Document is current
Any future updates will be listed below
-
Authors
Heimer, Maurice M.
Sun, Yuxin
Grosu, Sergio
Cyran, Clemens C.
Bonitatibus, Peter J. Jr
Okwelogu, Nikki
Bales, Brian C.
Meyer, Dan E.
Yeh, Benjamin M. https://orcid.org/0000-0003-2174-3009
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 21 August 2024
First Online: 4 October 2024
Declarations
:
: Animal experiments were approved by the VA San Francisco Institutional Animal Care and Use Committee (IACUC Protocol 22-003-01, approved Jan 27, 2022) and conducted in accordance with National Institutes of Health and USDA guidelines.
: Not applicable.
: YS holds stocks in Nextrast. CCC, activities related to the present article: disclosed no relevant relationships. Activities not related to the present article are on Siemens, the Healthineers advisory board, and the speaker’s bureau for Brainlab AG. BCB, activities related to the present article: disclosed no relevant relationships. Activities not related to the present article were a General Electric employee during the study period. Other relationships: disclosed no relevant relationships. DEM, activities related to the present article: disclosed no relevant relationships. Activities not related to the present article were a General Electric employee during the study period. Other relationships: disclosed no relevant relationships. BMY is a Nextrast board member; is a consultant for GE Healthcare; received grants from GE Healthcare and Philips Healthcare; served as a speaker for GE Healthcare; received royalties from patents on CT contrast agents; holds stock in Nextrast; and has been reimbursed for travel taken on behalf of Nextrast. For the remaining authors, none were declared.
